Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 5
1953 4
1954 2
1957 7
1958 2
1961 3
1962 1
1963 3
1966 1
1969 2
1970 1
1971 2
1973 4
1974 5
1976 6
1979 1
1980 3
1981 7
1982 1
1983 4
1985 3
1986 4
1987 1
1988 2
1989 4
1990 4
1991 6
1992 4
1993 4
1994 4
1995 6
1996 6
1997 7
1998 2
1999 7
2000 5
2001 2
2002 10
2003 7
2004 4
2005 6
2006 12
2007 5
2008 10
2009 3
2010 19
2011 22
2012 19
2013 6
2014 21
2015 23
2016 8
2017 10
2018 22
2019 16
2020 15
2021 17
2022 16
2023 21
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

407 results

Results by year

Filters applied: . Clear all
Page 1
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, Kitzman DW, Møller DV, Treppendahl MB, Verma S, Jensen TJ, Liisberg K, Lindegaard ML, Abhayaratna W, Ahmed FZ, Ben-Gal T, Chopra V, Ezekowitz JA, Fu M, Ito H, Lelonek M, Melenovský V, Merkely B, Núñez J, Perna E, Schou M, Senni M, Sharma K, van der Meer P, Von Lewinski D, Wolf D, Shah SJ; STEP-HFpEF DM Trial Committees and Investigators. Kosiborod MN, et al. N Engl J Med. 2024 Apr 18;390(15):1394-1407. doi: 10.1056/NEJMoa2313917. Epub 2024 Apr 6. N Engl J Med. 2024. PMID: 38587233 Clinical Trial.
Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial.
Ueki K, Sasako T, Okazaki Y, Kato M, Okahata S, Katsuyama H, Haraguchi M, Morita A, Ohashi K, Hara K, Morise A, Izumi K, Ishizuka N, Ohashi Y, Noda M, Kadowaki T; J-DOIT3 Study Group. Ueki K, et al. Lancet Diabetes Endocrinol. 2017 Dec;5(12):951-964. doi: 10.1016/S2213-8587(17)30327-3. Epub 2017 Oct 24. Lancet Diabetes Endocrinol. 2017. PMID: 29079252 Clinical Trial.
TRPV4 Regulates the Development of Psoriasis by Controlling Adenosine Triphosphate Expression in Keratinocytes and the Neuroimmune System.
Amalia SN, Baral H, Fujiwara C, Uchiyama A, Inoue Y, Yamazaki S, Ishikawa M, Kosaka K, Sekiguchi A, Yokoyama Y, Ogino S, Torii R, Hosoi M, Shibasaki K, Motegi SI. Amalia SN, et al. Among authors: hosoi m. J Invest Dermatol. 2023 Dec;143(12):2356-2365.e5. doi: 10.1016/j.jid.2023.05.009. Epub 2023 May 30. J Invest Dermatol. 2023. PMID: 37263487
Plasma Cholinesterase Activity in Alzheimer's Disease.
Hosoi M, Hori K, Konishi K, Tani M, Tomioka H, Kitajima Y, Akashi N, Inamoto A, Minami S, Izuno T, Umezawa K, Horiuchi K, Hachisu M. Hosoi M, et al. Neurodegener Dis. 2015;15(3):188-90. doi: 10.1159/000381532. Epub 2015 Jun 30. Neurodegener Dis. 2015. PMID: 26138498 Free article. Review.
Effects of Pycnogenol® in women with postmenopausal symptoms: a 90-day comparative study.
Cesarone MR, Belcaro G, Cornelli U, Hosoi M, Scipione V, Scipione C, Dugall M, Feragalli B, Pellegrini L, Cotellese R, Bottari A, Ledda A. Cesarone MR, et al. Among authors: hosoi m. Panminerva Med. 2023 Jun;65(2):129-132. doi: 10.23736/S0031-0808.22.04792-9. Epub 2023 Feb 21. Panminerva Med. 2023. PMID: 36800800 No abstract available.
[Lipid peroxide].
Hosoi M, Sato T, Fujii S. Hosoi M, et al. Nihon Rinsho. 2002 Aug;60 Suppl 8:451-5. Nihon Rinsho. 2002. PMID: 12355789 Review. Japanese. No abstract available.
Pycnogenol® prevents skin hyperpigmentation following sclerotherapy.
Cesarone MR, Belcaro G, Cox D, Scipione V, Scipione C, Dugall M, Cornelli U, Hosoi M, Feragalli B, Hu S, Cotellese R. Cesarone MR, et al. Among authors: hosoi m. Minerva Surg. 2024 Apr;79(2):161-165. doi: 10.23736/S2724-5691.23.10035-9. Minerva Surg. 2024. PMID: 38592434
Keratinocyte-Specific SOX2 Overexpression Suppressed Pressure Ulcer Formation after Cutaneous Ischemia-Reperfusion Injury via Enhancement of Amphiregulin Production.
Inoue Y, Uchiyama A, Amalia SN, Ishikawa M, Kosaka K, Sekiguchi A, Ogino S, Yokoyama Y, Torii R, Hosoi M, Akai R, Iwawaki T, Morasso MI, Motegi SI. Inoue Y, et al. Among authors: hosoi m. J Invest Dermatol. 2024 Jan;144(1):142-151.e5. doi: 10.1016/j.jid.2023.06.202. Epub 2023 Jul 28. J Invest Dermatol. 2024. PMID: 37516309
A Review of the Role of Anticholinergic Activity in Lewy Body Disease and Delirium.
Kitajima Y, Hori K, Konishi K, Tani M, Tomioka H, Akashi N, Hosoi M, Inamoto A, Hasegawa S, Kikuchi N, Takahashi A, Hachisu M. Kitajima Y, et al. Among authors: hosoi m. Neurodegener Dis. 2015;15(3):162-7. doi: 10.1159/000381522. Epub 2015 Jun 30. Neurodegener Dis. 2015. PMID: 26138494 Free article. Review.
407 results